Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 15, Pages 5484
Publisher
MDPI AG
Online
2020-08-03
DOI
10.3390/ijms21155484
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641.
- (2020) Julie Nicole Graff et al. JOURNAL OF CLINICAL ONCOLOGY
- Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
- (2020) Aleksei Titov et al. Cancers
- A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.
- (2019) Vivek Narayan et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
- (2019) Peter C.C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
- (2019) Sumanta Pal et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- IMPACT: Immunotherapy in patients with metastatic cancers and CDK12 mutations.
- (2019) Melissa Andrea Reimers et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).
- (2019) Yien Ning Sophia Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) James L. Mohler et al. Journal of the National Comprehensive Cancer Network
- Pan‐Cancer Analysis of CDK12 Loss‐of‐Function Alterations and Their Association with the Focal Tandem‐Duplicator Phenotype
- (2019) Ethan S. Sokol et al. ONCOLOGIST
- Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
- (2019) H. Taghizadeh et al. OncoImmunology
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
- (2018) A R Hansen et al. ANNALS OF ONCOLOGY
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
- (2018) Karim Boudadi et al. Oncotarget
- Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer
- (2018) Emmanuel S. Antonarakis NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations
- (2018) Emmanuel S. Antonarakis et al. EUROPEAN UROLOGY
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
- (2018) Saman Maleki Vareki Journal for ImmunoTherapy of Cancer
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
- (2017) Zoila Lopez-Bujanda et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase
- (2017) Irina Lerman et al. MOLECULAR CANCER RESEARCH
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
- (2017) Sheel Patel et al. OncoTargets and Therapy
- Pan-urologic cancer genomic subtypes that transcend tissue of origin
- (2017) Fengju Chen et al. Nature Communications
- Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications
- (2017) Yu-Pei Chen et al. Theranostics
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
- (2017) Pornpimol Charoentong et al. Cell Reports
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC).
- (2017) Susan F. Slovin et al. JOURNAL OF CLINICAL ONCOLOGY
- The Emerging Role of B Cells in Tumor Immunity
- (2016) Peiling Tsou et al. CANCER RESEARCH
- Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity
- (2016) Christine Pasero et al. CANCER RESEARCH
- Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
- (2016) R. M. Chabanon et al. CLINICAL CANCER RESEARCH
- Genomic determinants of cancer immunotherapy
- (2016) Diana Miao et al. CURRENT OPINION IN IMMUNOLOGY
- Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma
- (2016) Stefani Spranger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
- (2016) Richard P. Junghans et al. PROSTATE
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis
- (2016) Aerken Maolake et al. Oncotarget
- PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer
- (2016) Honggeng Guan et al. Scientific Reports
- Chronic inflammatory mediators enhance prostate cancer development and progression
- (2015) Dinesh Thapa et al. BIOCHEMICAL PHARMACOLOGY
- Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
- (2015) Jack Schalken et al. BJU INTERNATIONAL
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Suppressive effects of androgens on the immune system
- (2015) Abhishek Trigunaite et al. CELLULAR IMMUNOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- (2015) A M Martin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial
- (2014) B. Gurel et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer
- (2014) Manja Idorn et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sex steroid blockade enhances thymopoiesis by modulating Notch signaling
- (2014) Enrico Velardi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor infiltrating B-cells are increased in prostate cancer tissue
- (2014) Jason R Woo et al. Journal of Translational Medicine
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation
- (2014) Haydn T. Kissick et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor clone dynamics in lethal prostate cancer
- (2014) S. Carreira et al. Science Translational Medicine
- The Role of M1 and M2 Macrophages in Prostate Cancer in relation to Extracapsular Tumor Extension and Biochemical Recurrence after Radical Prostatectomy
- (2014) M. Lanciotti et al. Biomed Research International
- Chronic Inflammation and Cytokines in the Tumor Microenvironment
- (2014) Glauben Landskron et al. Journal of Immunology Research
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation
- (2013) Kouji Izumi et al. EMBO Molecular Medicine
- Prostatic atrophy: its spatial proximity to carcinoma and intraepithelial neoplasia based on annotation of digital slides
- (2013) Kenneth A. Iczkowski et al. HUMAN PATHOLOGY
- Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
- (2013) Gang Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men
- (2013) Alexandre R. Zlotta et al. JNCI-Journal of the National Cancer Institute
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Dark Side of Mast Cell-Targeted Therapy in Prostate Cancer
- (2012) P. Pittoni et al. CANCER RESEARCH
- Increased CD8+ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells
- (2012) S. Tang et al. CANCER RESEARCH
- The bright and the dark sides of activin in wound healing and cancer
- (2012) Maria Antsiferova et al. JOURNAL OF CELL SCIENCE
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
- (2009) Kathleen Ebelt et al. EUROPEAN JOURNAL OF CANCER
- CCL2 and Interleukin-6 Promote Survival of Human CD11b+Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization
- (2009) Hernan Roca et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
- (2009) Philippe O. Gannon et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma
- (2008) Mahmoud-Rezk A. Hussein et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search